Overview

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

Status:
Unknown status
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan University
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Etoposide phosphate
Gemcitabine
Ifosfamide
Isophosphamide mustard